{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:23:27Z","timestamp":1790634207377,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12325-021-01919-z","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T09:02:36Z","timestamp":1637830956000},"page":"598-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Population Pharmacokinetics and Exposure\u2013Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed\/Refractory and Previously Untreated Patients with Diffuse Large B\u00a0Cell Lymphoma"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct02055820","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-2044","authenticated-orcid":false,"given":"Divya","family":"Samineni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weize","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Gibiansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Rajwanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bazeos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"issue":"11","key":"1919_CR1","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1158\/0008-5472.CAN-13-3728","volume":"74","author":"AN Hata","year":"2014","unstructured":"Hata AN, Yeo A, Faber AC, et al. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 2014;74(11):3146\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3728.","journal-title":"Cancer Res"},{"key":"1919_CR2","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.180002","author":"KJ Campbell","year":"2018","unstructured":"Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018. https:\/\/doi.org\/10.1098\/rsob.180002.","journal-title":"Open Biol"},{"issue":"2","key":"1919_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s11670-011-0160-x","volume":"23","author":"HW Zhang","year":"2011","unstructured":"Zhang HW, Cheng NL, Chen ZW, Wang JF, Li SH, Bai W. Clinical impact of t(14;18) in diffuse large B-cell lymphoma. Chin J Cancer Res. 2011;23(2):160\u20134. https:\/\/doi.org\/10.1007\/s11670-011-0160-x.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"1919_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/2040620715608091","volume":"7","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Tsui A, Wall M, Huang DC, Roberts AW. Current challenges and novel treatment strategies in double hit lymphomas. Ther Adv Hematol. 2016;7(1):52\u201364. https:\/\/doi.org\/10.1177\/2040620715608091.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"1919_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138. https:\/\/doi.org\/10.1038\/nm.3048.","journal-title":"Nat Med"},{"issue":"9","key":"1919_CR6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Venetoclax: first global approval. Drugs. 2016;76(9):979\u201387. https:\/\/doi.org\/10.1007\/s40265-016-0596-x.","journal-title":"Drugs"},{"key":"1919_CR7","unstructured":"Venclexta (venetoclax) [package insert]. North Chicago, IL: AbbVie Inc; 2020. https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf"},{"issue":"8","key":"1919_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.70.4320.","journal-title":"J Clin Oncol"},{"key":"1919_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-880526","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Salles G, Mason KD, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019. https:\/\/doi.org\/10.1182\/blood-2018-11-880526.","journal-title":"Blood"},{"issue":"31","key":"1919_CR10","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529\u201337. https:\/\/doi.org\/10.1200\/JCO.2017.73.3402.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1919_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","volume":"137","author":"F Franck Morschhauser","year":"2021","unstructured":"Franck Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600\u20139.","journal-title":"Blood"},{"key":"1919_CR12","unstructured":"Zelenetz AD, Feugier P, Flinn, I et al. Improved outcomes with venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in previously untreated patients with BCL-2-positive diffuse large B-cell lymphoma (DLBCL): updated desults from the phase II CAVALLI Study. (Abstract). 61st ASH Annual meeting; December 7\u221210. Orlando, Florida. 2019"},{"issue":"5","key":"1919_CR13","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","volume":"18","author":"AK Jones","year":"2016","unstructured":"Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-hodgkin\u2019s lymphoma patients: a pooled population pharmacokinetic analysis. AAPS J. 2016;18(5):1192\u2013202. https:\/\/doi.org\/10.1208\/s12248-016-9927-9.","journal-title":"AAPS J"},{"issue":"2","key":"1919_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"issue":"9","key":"1919_CR15","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont C, Laveille C, Mentre F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036\u201349. https:\/\/doi.org\/10.1007\/s11095-006-9067-5.","journal-title":"Pharm Res"},{"issue":"2","key":"1919_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171\u201392.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1919_CR17","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User\u2019s Guides (1989\u20132011). Ellicott City, MD, USA: Icon Development Solutions; 2011"},{"issue":"11","key":"1919_CR18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jcph.741","volume":"56","author":"AH Salem","year":"2016","unstructured":"Salem AH, Agarwal SK, Dunbar M, et al. Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor. J Clin Pharmacol. 2016;56(11):1355\u201361. https:\/\/doi.org\/10.1002\/jcph.741.","journal-title":"J Clin Pharmacol"},{"key":"1919_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00788-8","author":"R Deng","year":"2019","unstructured":"Deng R, Gibiansky L, Lu T, et al. Bayesian population model of the pharmacokinetics of venetoclax in combination with rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia: results from the phase III MURANO study. Clin Pharmacokinet. 2019. https:\/\/doi.org\/10.1007\/s40262-019-00788-8.","journal-title":"Clin Pharmacokinet"},{"key":"1919_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2646","author":"S Agarwal","year":"2019","unstructured":"Agarwal S, Gopalakrishnan S, Mensing S, et al. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis. Hematol Oncol. 2019. https:\/\/doi.org\/10.1002\/hon.2646.","journal-title":"Hematol Oncol"},{"issue":"4","key":"1919_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00280-016-3144-1","volume":"78","author":"KJ Freise","year":"2016","unstructured":"Freise KJ, Dunbar M, Jones AK, et al. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemother Pharmacol. 2016;78(4):847\u201353. https:\/\/doi.org\/10.1007\/s00280-016-3144-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1919_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hon.2373","volume":"35","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Menon RM, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol. 2017;35(4):679\u201384. https:\/\/doi.org\/10.1002\/hon.2373.","journal-title":"Hematol Oncol"},{"issue":"6","key":"1919_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/cpt.712","volume":"102","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH. Moving beyond maximum tolerated dose for targeted oncology drugs: use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients. Clin Pharmacol Ther. 2017;102(6):970\u20136. https:\/\/doi.org\/10.1002\/cpt.712.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1919_CR24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/10428194.2017.1361024","volume":"59","author":"A Parikh","year":"2018","unstructured":"Parikh A, Gopalakrishnan S, Freise KJ, et al. Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2018;59(4):871\u20139. https:\/\/doi.org\/10.1080\/10428194.2017.1361024.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1919_CR25","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3346\/jkms.2014.29.11.1493","volume":"29","author":"YW Choi","year":"2014","unstructured":"Choi YW, Jeong SH, Ahn MS, et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci. 2014;29(11):1493\u2013500. https:\/\/doi.org\/10.3346\/jkms.2014.29.11.1493.","journal-title":"J Korean Med Sci"},{"issue":"22","key":"1919_CR26","doi-asserted-by":"publisher","first-page":"19316","DOI":"10.18632\/oncotarget.2909","volume":"6","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Eaton AA, Gounder MM, et al. Predictors of early treatment discontinuation in patients enrolled on phase I oncology trials. Oncotarget. 2015;6(22):19316\u201327. https:\/\/doi.org\/10.18632\/oncotarget.2909.","journal-title":"Oncotarget"},{"issue":"Suppl 5","key":"1919_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492187","volume":"41","author":"A Matzdorff","year":"2018","unstructured":"Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia\u2014current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41(Suppl 5):1\u201330. https:\/\/doi.org\/10.1159\/000492187.","journal-title":"Oncol Res Treat"},{"issue":"24","key":"1919_CR28","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","volume":"116","author":"M Pfreundschuh","year":"2010","unstructured":"Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116(24):5103\u201310. https:\/\/doi.org\/10.1182\/blood-2010-07-259333.","journal-title":"Blood"},{"issue":"10","key":"1919_CR29","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s12325-017-0610-z","volume":"34","author":"A Davies","year":"2017","unstructured":"Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34(10):2210\u201331. https:\/\/doi.org\/10.1007\/s12325-017-0610-z.","journal-title":"Adv Ther"},{"issue":"10","key":"1919_CR30","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232\u201373. https:\/\/doi.org\/10.1007\/s12325-017-0612-x.","journal-title":"Adv Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01919-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01919-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01919-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T08:45:35Z","timestamp":1643359535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01919-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1919"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01919-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"5 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}